In this Nov. 16, 2020 file photo a man wearing a mask passes the New York Stock Exchange in New York. Stocks are opening moderately lower on Wall Street, edging below the record highs they set a day earlier. The S&P 500 fell 0.4% shortly after the opening bell Wednesday, Dec. 2. (AP Photo/Mark Lennihan, File)
U.S. stock indexes are mixed in afternoon trading Wednesday, easing off a fresh set of record highs reached on optimism that coronavirus vaccines could soon start driving a stronger economic recovery.
The S&P 500 was little changed a day after opening December with a bang. It closed at a record high of 3,662.45 on Tuesday. The Nasdaq composite, which also opened the month with a new record, slipped 0.3%. The Dow Jones Industrial Average was down 26 points, or 0.1%, to 29,750 as of 1:02 p.m. Eastern time.
Technology companies were the biggest drag on the market. Salesforce.com fell 7.8% after announcing a deal late Tuesday to buy messaging platform Slack for $27.7 billion. Microsoft fell 1%. The sector has been leading the market higher since the pandemic started wreaking havoc on the global economy, but hopes for a vaccine and return to economic normalcy have been shifting money toward companies whose profits are more closely tied to the economy’s strength.
Pfizer and BioNTech said they’ve won permission for emergency use of their COVID-19 vaccine in Britain, the world’s first coronavirus shot that’s backed by rigorous science and a major step toward eventually ending the pandemic. The move makes Britain one of the first countries to begin vaccinating its population against the virus. The companies have already asked for approval to begin vaccinations in the U.S. in December.
Meanwhile, Moderna is also asking U.S. and European regulators to allow emergency use of its COVID-19 vaccine.
The positive developments on the vaccine front are helping to lift health care stocks. Pfizer Inc. rose 3.5% and insurer UnitedHealth Group rose 2.7%.
Stocks have been ramping higher in recent weeks as investors focus on the possibility that coronavirus vaccines could soon help usher in a fuller global economic recovery. Traders are also holding out hope that Democrats and Republicans may reach a deal on some amount of economic stimulus for the economy before 2021, though the parties remain divided on the details and the cost.
Unemployment remains high as the COVID-19 outbreak widens the gulf between average people and the wealthiest Americans. Payroll processor ADP said Wednesday that private U.S. employers added 307,000 jobs last month. That fell short of Wall Street analysts' expectations for a gain of 405,000 jobs, according to FactSet. The Labor Department issues its job data for November on Friday. Economists are forecasting that report will show the economy added about 441,000 jobs, down from a gain of 638,000 in October.
Lyft climbed 5.8% after the ride-hailing company posted a smaller loss this quarter and better margins. The news helped boost rival Uber Technologies up 3.4%.
Treasury yields headed higher, giving banks a boost because they allow them to charge more lucrative interest rates on loans. The yield on the 10-year Treasury rose to 0.96% from 0.92% late Tuesday. JPMorgan Chase rose 1.2% and Citigroup gained 2.9%.
Germany's DAX shed 0.5% and France's CAC 40 was flat. In Britain, the FTSE 100 rose 1.2%. Markets in Asia were mixed.
Before you consider Lyft, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyft wasn't on the list.
While Lyft currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report